What Is IGF-1 and Why Do Researchers Measure It Alongside GH Peptides

Growth hormone is released in pulses and remains in circulation for only a short time. Its level can change sharply within minutes, so one blood sample may not show sustained GH axis activity. IGF-1 offers a more stable signal because it reflects GH stimulation over a longer period. For this reason, studies involving research peptides examine IGF-1 and GH peptides together to confirm whether the GH axis has produced a measurable downstream response.

Note: This content is provided for educational purposes within a research context only. It does not promote or suggest the use of peptides for personal, medical, or non-research applications.

What Is IGF-1?

To explain what IGF-1 is, it is useful to place it within the growth hormone axis. Insulin-like growth factor 1 is a 70-amino acid peptide hormone, historically called somatomedin C. Many tissues produce it, but hepatocytes in the liver provide most circulating IGF-1. This link between IGF-1 liver production and somatomedin activity reflects downstream GH signaling.

IGF-1 binds to the IGF-1 receptor, a receptor tyrosine kinase. It then activates two main signaling pathways. PI3K/Akt/mTOR is linked to protein synthesis and cell survival, while Ras/MAPK/ERK supports cell proliferation and differentiation.

Around 80–90% of circulating IGF-1 binds to IGFBP-3 and an acid-labile subunit. This ternary complex slows its breakdown and extends its time in circulation. The IGF-1 IGFBP binding proteins system is therefore central to the stability of measured IGF-1.

How GH Drives IGF-1 Production

Growth hormone is released from somatotroph cells in the anterior pituitary. This release happens in pulses rather than at a steady rate. Pulse size and frequency vary with age, sex, sleep stage, and nutritional status. The pulsatile GH IGF-1 response helps explain why direct GH measurements can change sharply within a short period.

After release, GH reaches the liver and binds to growth hormone receptors on hepatocytes. This activates the JAK2/STAT5b signaling route and increases transcription of the IGF-1 gene. The IGF-1 and growth hormone relationship is not a simple one-to-one process. The liver combines signals from repeated GH pulses, so a small change in pulse strength may produce a larger change in circulating IGF-1.

Researchers can activate this axis through two main receptor routes. A closer look at GHRH and ghrelin receptor signaling shows how both routes affect pituitary GH release through different receptor targets.

The Main Research Compounds Within These Two Classes

• CJC-1295 with DAC is a GHRH analog studied for its extended signaling profile.
• Sermorelin also targets the GHRH receptor and is used to examine pituitary GH release in laboratory models.
• Ipamorelin activates GHSR-1a and allows researchers to study GH release through the ghrelin receptor route.
• GHRP-2 is another GHSR-1a agonist used to assess GH pulse responses and downstream IGF-1 changes.
• GHRP-6 belongs to the same receptor class and is used to compare secretagogue activity in controlled models.
• Hexarelin is used in laboratory models to examine GHSR-1a signaling and its effect on the GH axis.

Although these compounds act through different receptors, both peptide classes can increase GH release. Researchers can then measure the resulting IGF-1 response as a downstream sign of GH axis activation.

Peptide Class	Receptor Target	Signaling Mechanism	IGF-1 Research Relevance	Example Compounds
GHRH analogs	GHRHR	Activates pituitary GHRH signaling	Shows downstream IGF-1 changes after GH release	CJC-1295, Sermorelin
Ghrelin receptor agonists	GHSR-1a	Activates ghrelin receptor signaling in somatotrophs	Supports comparisons through a separate receptor route	Ipamorelin, GHRP-2, GHRP-6, Hexarelin

Why Researchers Measure IGF-1 Instead of GH

Researchers measure IGF-1 because it overcomes several limitations of direct GH testing. Growth hormone has a plasma half-life of about 20 minutes and is released in pulses throughout the day. A single blood sample captures only one moment and may miss sustained GH axis activity entirely. IGF-1, by contrast, reflects the combined effect of GH signaling over the previous 24 hours or more — and remains stable enough that sample timing matters far less than with direct GH measurement.

• IGF-1 captures responses that a single GH measurement may miss. Studies involving CJC-1295 with DAC found that circulating IGF-1 remained elevated for 9–11 days after a single administration, while GH continued to fluctuate in short pulses. IGF-1 therefore provides a clearer picture of the downstream response.
• Binding proteins affect interpretation. Nutritional status, thyroid function, liver function, and estrogen can all influence IGFBP levels. A change in measured IGF-1 may therefore reflect altered GH signaling, altered binding protein dynamics, or both — and researchers should account for this when comparing results across studies.

IGF-1 and the Splice Variant Picture: Where MGF Fits

The IGF-1 gene produces several isoforms through alternative splicing. Circulating blood measurements mainly reflect the liver-derived IGF-1Ea form, while MGF refers to IGF-1Ec, a splice variant expressed locally in mechanically responsive tissues. Its expression increases briefly after tissue loading or damage, and its E-peptide has been studied for its role in satellite cell activity.

MGF represents a different research target from circulating IGF-1. Blood IGF-1 measurements reflect systemic GH axis activity, but they do not measure local MGF expression. Researchers should account for this difference when designing studies or interpreting results.

What This Means for GH Peptide Research Design

IGF-1 is a standard downstream marker in GH secretagogue studies, but it should be interpreted as evidence of GH axis engagement rather than a direct measurement of GH secretion.

To improve consistency across experiments, researchers should:

• collect samples under standardized conditions, such as a morning fasting draw;
• use the same assay format and laboratory throughout the study, since different immunoassays can produce different absolute IGF-1 values;
• interpret combination studies carefully, as models using compounds such as CJC-1295 and Ipamorelin may produce larger increases in circulating IGF-1 than either compound alone.

IGF-1 as a Research Endpoint in GH Peptide Studies

Understanding IGF-1 and GH peptides is essential for interpreting GH secretagogue research. GH changes rapidly and is difficult to evaluate with one measurement. IGF-1 provides a more stable marker of cumulative GH axis activity. Researchers must still consider binding proteins, assay methods, and the difference between circulating IGF-1 and local splice variants. When these factors are assessed together, IGF-1 provides a useful endpoint for studying GH axis signaling in controlled laboratory research.

Research References

• Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of Growth Hormone-Releasing Hormone, in Healthy Adults. The Journal of Clinical Endocrinology & Metabolism. 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
• Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The Somatomedin Hypothesis: 2001. Endocrine Reviews. 2001. https://academic.oup.com/edrv/article/22/1/53/2424115
• Juul A. Serum Levels of Insulin-Like Growth Factor I and Its Binding Proteins in Health and Disease. Growth Hormone & IGF Research. 2003. https://pubmed.ncbi.nlm.nih.gov/12914749/
• Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration. Endocrinology. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC2840678/
• Bailes J, Soloviev M. Insulin-Like Growth Factor-1 and Its Monitoring in Medical Diagnostics and Sports. Biomolecules. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC7913862/

What is IGF-1 and what does it do?

IGF-1 is a 70-amino acid peptide hormone produced mainly by the liver after growth hormone stimulation. Most circulating IGF-1 binds to IGFBP-3 and an acid-labile subunit, which extends its time in circulation. It signals through the IGF-1 receptor and activates pathways involved in protein synthesis, cell survival, proliferation, and differentiation in laboratory models.

Why do researchers measure IGF-1 instead of GH directly?

Growth hormone has a plasma half-life of about 20 minutes and is released in pulses, making a single blood sample difficult to interpret. IGF-1 reflects the combined effect of GH signaling over the previous 24 hours or longer and remains relatively stable throughout the day. Because of this, researchers commonly use IGF-1 as the downstream marker of GH axis activity.

What are IGF binding proteins and how do they affect measurement?

Most circulating IGF-1 is bound to IGF binding proteins, especially IGFBP-3. These proteins protect IGF-1 from rapid breakdown and extend its time in circulation. However, IGFBP levels can change with nutritional status, thyroid function, liver function, and estrogen levels. Researchers should consider these factors because measured IGF-1 values may reflect both GH signaling and changes in binding protein dynamics.

How does circulating IGF-1 differ from MGF?

Circulating IGF-1 mainly represents the liver-derived IGF-1Ea isoform and reflects systemic GH axis activity. MGF, also known as IGF-1Ec in humans, is a locally expressed splice variant produced in mechanically responsive tissues. Because they represent different biological processes, circulating IGF-1 measurements cannot be used as a direct substitute for local MGF expression.